Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Astellas Options Gene Therapy for Rare Disease in $2.2bn Deal

publication date: Oct 8, 2024

Tokyo’s Astellas Pharma signed an option to acquire global rights for a neurology gene therapy from AviadoBio of London. The candidate, AVB-101, is an AAV-based gene therapy currently in a Phase I/II trial for patients with a frontotemporal dementia with mutations in progranulin (FTD-GRN). Astellas will invest $20 million in AviadoBio and pay $30 million in upfront payments to acquire the option. If the option is exercised, AviadoBio is eligible for up to $2.2 billion in license fees and milestones plus royalties.More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here